TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28441522

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Alcohol-free placebo drink
Number of subjects: 62

Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 62
Study: 25692656

Group type: EXPERIMENTAL
Intervention: Freeze dried live attenuated Oka strain Varicella Vaccine (VR 795 Oka strain)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Varilrix (Oka-RIT strain)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Freeze dried live attenuated Oka strain Varicella Vaccine (VR 795 Oka strain) and Varilrix (Oka-RIT strain)
Number of subjects: 268
Study: 24245914

Group type: EXPERIMENTAL
Intervention: Aquatic physical exercise program in a thermal pool, 3 times per week over 2 months
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study: 20334535

Group type: EXPERIMENTAL
Intervention: SAR 1118 0.3%
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SAR 1118 0.1%
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SAR 1118 1.0%
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SAR 1118 5.0%
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 18509557

Group type: EXPERIMENTAL
Intervention: Manual therapy (anterior‐posterior joint mobilization over the talus) plus standard physiotherapy programme
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard physiotherapy programme only
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Manual therapy plus standard physiotherapy programme
Number of subjects: 94
Study: 17138733

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 15
Study: 14723416

Group type: EXPERIMENTAL
Intervention: Australian National Death Index (NDI)
Number of subjects: 5821

Group type: EXPERIMENTAL
Intervention: Australian National Death Index (NDI) for cardiovascular deaths
Number of subjects: 5821

Group type: EXPERIMENTAL
Intervention: Australian National Death Index (NDI) for cancer deaths
Number of subjects: 5821
Study: 9808226

Group type: EXPERIMENTAL
Intervention: Diet A (10 servings of fruit and vegetables each day for 15 days)
Number of subjects: 36
Study: 7751524

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical treatment with atropine
Number of subjects: 0
Study: 2717665

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5-HT agonist (fluoxetine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5-HT antagonist (ritanserin)
Number of subjects: 24
Study: 142468

Group type: EXPERIMENTAL
Intervention: Isosorbide (osmotic anti-glaucoma medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what control was used)
Number of subjects: 0
Study: 31915792

Group type: EXPERIMENTAL
Intervention: Right renal artery length
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Left renal artery length
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diameters of left renal artery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diameters of right renal artery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Renal artery diameters
Number of subjects: 50
Study: 31438412

Group type: EXPERIMENTAL
Intervention: Mobile application for medication management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28746725

Group type: EXPERIMENTAL
Intervention: Powdered beef liver
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Beef meat
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Beef liver + meat
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 23506189

Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postural orientation
Number of subjects: 60
Study: 22577108

Group type: EXPERIMENTAL
Intervention: Cinacalcet (30 mg daily, titrated until calcium normalization)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cinacalcet (for 3 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19485586

Group type: EXPERIMENTAL
Intervention: Medication-only condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined medication plus cognitive-behavioral therapy (CBT) condition
Number of subjects: 0
Study: 17543129

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (2.5 mgr)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine (1 mgr)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 27
Study: 15502430

Group type: EXPERIMENTAL
Intervention: Smoking cessation program consisting of 9 sessions focusing on self-efficacy, stress management, correction of distorted thoughts, consciousness raising, and assertiveness training.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 43
Study: 11684535

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (containing RDA or 1.5 times RDA of various vitamins and minerals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9821232

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5‐10 mg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Captopril 100 mg twice a day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 21
Study: 8121291

Group type: EXPERIMENTAL
Intervention: Mepacrine hydrochloride 100 mg three times daily for 7 days
Number of subjects: 16
Study: 2818418

Group type: EXPERIMENTAL
Intervention: skin‐resistance‐level biofeedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: false‐feedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: no‐feedback
Number of subjects: 30
Study: 403562

Group type: EXPERIMENTAL
Intervention: Tandamine hydrochloride
Number of subjects: 0
Study: 31443732

Group type: EXPERIMENTAL
Intervention: Peer mentoring intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social support control
Number of subjects: 0
Study: 29139337

Group type: EXPERIMENTAL
Intervention: Error-based learning (EBL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Errorless learning (ELL)
Number of subjects: 54
Study: 26391664

Group type: EXPERIMENTAL
Intervention: Diallil‐Tiosulphinate, Nucipherine and Diosgenin on alternate days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23383047

Group type: EXPERIMENTAL
Intervention: lopinavir/r (LPV/r)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 71

Group type: COMPARATOR
Intervention: antibiotic use
Number of subjects: 71
Study: 20574663

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.25 mg intravenously) and dexamethasone (8 mg intravenously) on day 1
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.25 mg intravenously) and dexamethasone (8 mg intravenously) on day 1 followed by dexamethasone 8 mg orally on days 2 and 3
Number of subjects: 332

Group type: COMPARATOR
Intervention: Palonosetron plus dexamethasone on day 1
Number of subjects: 332

Group type: COMPARATOR
Intervention: Palonosetron plus dexamethasone on days 1, 2, and 3
Number of subjects: 332
Study: 19522441

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AED) with accurate pathogenic targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diets as alternatives to AED
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modern technologies (MRI and PET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General care improvements
Number of subjects: 0
Study: 17092377

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no orlistat)
Number of subjects: 10
Study: 17140540

Group type: EXPERIMENTAL
Intervention: Dental treatment (full mouth rehabilitation under general anaesthesia)
Number of subjects: 115
Study: 14675922

Group type: EXPERIMENTAL
Intervention: Contact Laser Vaporization (CLV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Transurethral Resection of the Prostate (TURP)
Number of subjects: 52
Study: 10705631

Group type: EXPERIMENTAL
Intervention: 0.5 mg of octreotide‐acetate subcutaneously one hour prior to ERCP
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 0.5 mg of octreotide‐acetate
Number of subjects: 209
Study: 7560226

Group type: EXPERIMENTAL
Intervention: Systemic Augmentin therapy (500 mg 1 h prior to surgery, 500 mg TID for 8 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no systemic antimicrobial therapy)
Number of subjects: 18
Study: 1697419

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ritanserin (20 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 6986240

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (aluminum hydroxide and magnesium oxide)
Number of subjects: 167
Study: 30999929

Group type: EXPERIMENTAL
Intervention: Namilumab 150 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Namilumab 20 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Namilumab 80 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Namilumab (all doses)
Number of subjects: 108
Study: 28626201

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 717

Group type: COMPARATOR
Intervention: CRT-P
Number of subjects: 717
Study: 24794075

Group type: EXPERIMENTAL
Intervention: Baseline PSA <1.0 ng/ml
Number of subjects: 4350

Group type: EXPERIMENTAL
Intervention: Baseline PSA 1-1.9 ng/ml
Number of subjects: 4350

Group type: EXPERIMENTAL
Intervention: Baseline PSA 2-2.9 ng/ml
Number of subjects: 4350

Group type: EXPERIMENTAL
Intervention: Baseline PSA 1-1.99 ng/ml
Number of subjects: 4350

Group type: EXPERIMENTAL
Intervention: Baseline PSA 2-2.99 ng/ml
Number of subjects: 4350
Study: 22718472

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), 10 sessions, 830 nm, output power of 50 mW, fluence of 707 J/cm² (L group, n=23)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo treatment (P group, n=20)
Number of subjects: 43
Study: 22142317

Group type: EXPERIMENTAL
Intervention: Antimicrobial-coated sutures
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional sutures (polyglactin and poliglecaprone)
Number of subjects: 150
Study: 19261230

Group type: EXPERIMENTAL
Intervention: Naltrexone (ReVia) and acamprosate (Campral)
Number of subjects: 1226
Study: 17908563

Group type: EXPERIMENTAL
Intervention: 4-week ball exercise program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no rehabilitation training)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Experimental group vs Control group
Number of subjects: 25
Study: 15687761

Group type: EXPERIMENTAL
Intervention: Educational program for coping with problem situations (4 weeks, total 8 hours)
Number of subjects: 31
Study: 11723983

Group type: EXPERIMENTAL
Intervention: BTE Primus grip attachment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Jamar dynamometer
Number of subjects: 26

Group type: COMPARATOR
Intervention: Body position (sitting vs standing)
Number of subjects: 26
Study: 8988795

Group type: EXPERIMENTAL
Intervention: dextroamphetamine (0.25 mg/kg p.o.) + scopolamine (0.5 mg i.v.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo + scopolamine
Number of subjects: 17
Study: 8480681

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (900 mg/d for 4 mo)
Number of subjects: 25
Study: 3435009

Group type: EXPERIMENTAL
Intervention: Faecal occult blood (FOB) tests
Number of subjects: 26975

Group type: COMPARATOR
Intervention: Control group managed by family doctors in standard manner
Number of subjects: 26975
Study: 30425326

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (2 hours/week for 8 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Health education talks (control group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 42
Study: 27909882

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program
Number of subjects: 409
Study: 26058920

Group type: EXPERIMENTAL
Intervention: HPgV detection among healthy blood donors
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: HPgV detection among HBV-infected patients
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Overall HPgV infection rate in Qatar
Number of subjects: 714

Group type: COMPARATOR
Intervention: Comparison of HPgV infection rates
Number of subjects: 714

Group type: COMPARATOR
Intervention: Association of HPgV infection with demographic factors
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Genotyping of HPgV
Number of subjects: 714
Study: 23562220

Group type: EXPERIMENTAL
Intervention: HIV/STI/pregnancy prevention curriculum only
Number of subjects: 765

Group type: COMPARATOR
Intervention: Service learning only
Number of subjects: 765

Group type: COMPARATOR
Intervention: HIV/STI/pregnancy prevention curriculum plus service learning
Number of subjects: 765

Group type: COMPARATOR
Intervention: Attention control curriculum
Number of subjects: 765
Study: 21666159

Group type: EXPERIMENTAL
Intervention: Attenuvax at 6 months of age (2D)
Number of subjects: 110

Group type: COMPARATOR
Intervention: MMRII at 12 months of age (1D)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: MMRII at 12 months of age (2D)
Number of subjects: 110
Study: 19211454

Group type: EXPERIMENTAL
Intervention: 24 additional months of androgen deprivation therapy
Number of subjects: 1554

Group type: COMPARATOR
Intervention: No additional therapy (control arm)
Number of subjects: 1554
Study: 16394038

Group type: EXPERIMENTAL
Intervention: Oxytocin (2.99 IU rapid intravenous infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxytocin (maximum infusion dose 10.3 +/‐ 8.2 mU/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxytocin (additional boluses as required)
Number of subjects: 30
Study: 19780299

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy regimens
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with IP cisplatin
Number of subjects: 3

Group type: COMPARATOR
Intervention: Carboplatin-based regimen
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard therapy with intravenous cisplatin plus paclitaxel
Number of subjects: 3
Study: 11953732

Group type: EXPERIMENTAL
Intervention: Increased sedentary behaviors
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Decreased sedentary behaviors
Number of subjects: 13

Group type: COMPARATOR
Intervention: Baseline sedentary behaviors
Number of subjects: 13
Study: 11475726

Group type: EXPERIMENTAL
Intervention: Fuzheng Baozhen Decoction (FZBZD)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Zhenqi Fuzheng Granules
Number of subjects: 117

Group type: COMPARATOR
Intervention: Radio- and chemotherapy alone
Number of subjects: 117
Study: 7866914

Group type: EXPERIMENTAL
Intervention: 50 IU SMC I.M.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2768576

Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 32
Study: 780061

Group type: COMPARATOR
Intervention: salbutamol 8 mg tablets (2 tablets b.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: aminophylline 225 mg tablets (1 tablet b.d. increasing to 2 tablets b.d. after 1 week)
Number of subjects: 18
Study: 31919501

Group type: EXPERIMENTAL
Intervention: Chronic seton drainage for 1 year
Number of subjects: 44

Group type: COMPARATOR
Intervention: Anti-TNF therapy for 1 year
Number of subjects: 44

Group type: COMPARATOR
Intervention: Surgical closure after 2 months under a short course anti-TNF
Number of subjects: 44
Study: 30944458

Group type: EXPERIMENTAL
Intervention: sorafenib-GEMOX
Number of subjects: 94

Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 94
Study: 29381988

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 172

Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 172
Study: 26355382

Group type: EXPERIMENTAL
Intervention: Early-discharge patients
Number of subjects: 178

Group type: COMPARATOR
Intervention: Inpatient controls
Number of subjects: 178
Study: 23571643

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Non-surgical interventions
Number of subjects: 212

Group type: COMPARATOR
Intervention: Normal-weight women (smokers)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Obese women
Number of subjects: 212
Study: 21768582

Group type: EXPERIMENTAL
Intervention: Percent format
Number of subjects: 2944

Group type: COMPARATOR
Intervention: Natural frequency format
Number of subjects: 2944

Group type: COMPARATOR
Intervention: Variable frequency format
Number of subjects: 2944
Study: 20112492

Group type: EXPERIMENTAL
Intervention: Dan an tang (chronic‐cholecystitis‐relieving decoction)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Xiao yan li dan Pian (bile‐draining anti‐inflammatory tablet)
Number of subjects: 160
Study: 17078734

Group type: EXPERIMENTAL
Intervention: Group A - rapidity of replantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group B - elimination of necrotic pulp and irritating stimuli
Number of subjects: 20
Study: 14723643

Group type: EXPERIMENTAL
Intervention: Transitional discharge model (including peer support and overlap of inpatient and community staff)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 0
Study: 10892914

Group type: EXPERIMENTAL
Intervention: Pleural tent procedure
Number of subjects: 50
Study: 8629630

Group type: EXPERIMENTAL
Intervention: mupirocin calcium ointment 2% applied daily to the exit site
Number of subjects: 82

Group type: COMPARATOR
Intervention: cyclic oral rifampin 600 mg for 5 days every 3 months
Number of subjects: 82
Study: 1592640

Group type: EXPERIMENTAL
Intervention: Gamma-nail
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 100
Study: 6691784

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (N = 14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (N = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cognitive therapy and Pharmacotherapy (N = 28)
Number of subjects: 28
Study: 31064968

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy during chemotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (0.9% normal saline gargles three times before meals)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 28620848

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-Care (SoC) platinum-based chemotherapy
Number of subjects: 0
Study: 27137715

Group type: EXPERIMENTAL
Intervention: Naloxegol (8, 15, 30, 60, 125, 250, 500, and 1000mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Naloxegol (250 and 1000mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Naloxegol (up to 1000mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Naloxegol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 23798725

Group type: COMPARATOR
Intervention: telcagepant 600 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: sumatriptan 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: telcagepant 600 mg with sumatriptan 100 mg
Number of subjects: 24
Study: 22041444

Group type: EXPERIMENTAL
Intervention: Rapid paraffin sections (group A)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Conventional paraffin sections (group B)
Number of subjects: 176
Study: 19208459

Group type: EXPERIMENTAL
Intervention: Arformoterol 15microg BID
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Tiotropium 18microg QD
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Combined therapy (arformoterol 15microg BID and tiotropium 18microg QD)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 234
Study: 16445833

Group type: EXPERIMENTAL
Intervention: Patient Self-Management (PSM)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Patient Self-Testing (PST)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Individual patients
Number of subjects: 104
Study: 16214453

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 11054
Study: 11131273

Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg daily for 8 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nitrendipine 5-10 mg daily for 8 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nitrendipine 5-10 mg daily for 8 weeks followed by Lisinopril 10-20 mg daily for another 8 weeks
Number of subjects: 17
Study: 9078198

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1202
Study: 1606777

Group type: COMPARATOR
Intervention: rHuEpo 40 U/kg intravenously three times weekly (Group 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rHuEpo 40 U/kg intravenously three times weekly with nandrolone decanoate 2 mg/kg weekly (Group 2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (Group 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (Group 2)
Number of subjects: 12
Study: 3982646

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2832549

Group type: EXPERIMENTAL
Intervention: Cisplatin 20 mg/m2 X 4 plus etoposide (VP‐16) 100 mg/m2 X 4 every 4 weeks for two courses
Number of subjects: 160

Group type: COMPARATOR
Intervention: No further therapy (control)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cisplatin plus VP‐16
Number of subjects: 160
Study: 31813045

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 20